MediciNova's Abstract on MN-166 in COMBAT-ALS Accepted for 2024 NEALS Meeting

MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (MNOV) and the Tokyo Stock Exchange (Code Number: 4875), has announced the acceptance of an abstract for presentation at the 2024 Annual NEALS Meeting. This abstract pertains to the ongoing clinical trial of MN-166 (ibudilast) for treating Amyotrophic Lateral Sclerosis (ALS). The presentation will occur in a poster format, led by Principal Investigator Dr. Björn Oskarsson, a recognized Associate Professor of Neurology and Director at the ALS Center of Excellence in Jacksonville, Florida. Scheduled between October 21-24, 2024, the hybrid event will take place in Clearwater, Florida, and online.

The study, identified by Submission ID 164, will be presented on October 23, 2024. Titled "COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Study Design and Trial Update," it will provide insights into the design and recent developments of the trial.

MN-166 (ibudilast) is a small molecule inhibitor targeting phosphodiesterase type-4 (PDE4) and inflammatory cytokines like macrophage migration inhibitory factor (MIF). It is currently in advanced clinical stages for various neurodegenerative diseases, including ALS, progressive multiple sclerosis (MS), and degenerative cervical myelopathy (DCM). Additionally, MN-166 is being explored for conditions such as glioblastoma, Long COVID, chemotherapy-induced peripheral neuropathy (CIPN), and substance use disorder. Some trials have also focused on patients at risk of developing acute respiratory distress syndrome (ARDS).

MediciNova, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative small molecule therapies aimed at treating inflammatory, fibrotic, and neurodegenerative diseases. Their late-stage pipeline is built around two primary compounds: MN-166 (ibudilast) and MN-001 (tipelukast), both exhibiting multiple mechanisms of action and strong safety profiles. Presently, MediciNova has 11 clinical development programs.

The company's lead asset, MN-166 (ibudilast), is in Phase 3 trials for ALS and DCM and is set for Phase 3 for progressive MS. Moreover, MN-166 is under Phase 2 trials for Long COVID and substance dependence. Another key compound, MN-001 (tipelukast), has been tested in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF), and another Phase 2 trial for metabolic-associated fatty liver disease (MAFLD) is ongoing. MediciNova has a history of securing investigator-sponsored clinical trials funded through government grants.

The focus of MediciNova on expanding its clinical-stage pipeline underscores its commitment to addressing unmet medical needs in neurodegenerative and inflammatory diseases. The acceptance of the abstract for the 2024 Annual NEALS Meeting sheds light on the ongoing efforts and progress in developing MN-166 (ibudilast) as a potential treatment for ALS. The presentation by Dr. Björn Oskarsson will likely provide significant insights into the study's design and recent updates, contributing to the broader medical and scientific community's understanding of ALS therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!